Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

124.03

+0.49 (0.40%)

as of Jul 13, 2026, 8:00:00 pm Market Open.

311 watching

Investor Insights

Jul 13, 2026, 12:00 am

This summary was created by AI, based on 22 opinions in the last 12 months.

Merck & Company (MRK) is regarded as a strong investment opportunity, primarily due to its robust drug pipeline and significant growth potential despite challenges with its blockbuster drug, Keytruda, which is set to go off-patent in 2028. Analysts highlight the company's anticipated increase in sales, particularly from Keytruda and other new drugs in development. While some concerns exist regarding market fluctuations and pricing clarity, a substantial number of experts maintain an optimistic outlook on the stock's performance. With a promising array of drugs poised for release by 2030 and solid financial metrics, including rising cash reserves and share buybacks, MRK is projected to see continued growth, making it a compelling choice for healthcare investors. Expert recommendations suggest a prudent approach to stop-loss levels and target price adjustments.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfeizer, PFE

TOP PICK

Trading at a significant discount.Has been getting left behind.

PAST TOP PICK

(Was a top pick on May 21/03. Up 4.4%.) Still likes. Offers good value.

TOP PICK

2.5% dividend. Big name products. Only 14/15 X next years earnings. Recent studies suggest that some of their drugs may also be useful in preventing cancer.

TOP PICK

Trading at 16 X earnings, yielding 2.6%. Great pipeline of new drugs. Great balance sheet.

BUY

Good price. Good earnings price momentum.

TOP PICK

Health care sector is a good sector. 15/16 PE. Good price.

WEAK BUY

Some of their drugs have come off patent and they are having difficulty with Research /Development productivity. Prefers Pfizer.

TOP PICK

Pharmaceuticals look good in any upturn. 3% dividend. Trading at 15 X earnings. Had no earnings growth this year.

BUY

Demographics for pharmaceuticals is good. Could be volatile during their election period. Good long term.

BUY

Likes the valuations. Good balance sheet and good earnings.

BUY

Outlook for drug companies is good. A bit expensve, but long term is good.

BUY

Sector has been hit hard. At a good level. Prefers Pfizer.

PAST TOP PICK

(Was a top pick on Apr 4 up 1.5%) Still likes.

DON'T BUY

Very reasonable valuation. Patents are coming off. Prefers Pfizer.

DON'T BUY

Fairly cheap. Dividend. Several drugs coming off patent.

Showing 271 to 285 of 305 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Dan Rohinton

iA Global Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)